Vivakor, Inc., today announced it has completed an exclusive distribution agreement with consumer product specialist, Regeneca International, Inc. (www.regeneca.com) for one of its proprietary, cutting-edge nutraceutical formulations. In conjunction with this agreement was an immediate purchase order from Regeneca for 25,000 units of the product. Both companies hope this agreement initiates a long term relationship for product commercialization. This purchase also represents to another substantial revenue stream for Vivakor's emerging nutraceutical division. Vivakor CEO Tannin Fuja expressed his enthusiasm for the transaction. "We are very excited for the possibilities of Vivakor's line of nutraceutical products. Worldwide demand for nutraceutical products is expected to exceed $15 billion and Vivakor plans on being a substantial player in that market."
Dr. Fuja continued, "We are particularly pleased to include in our new formulation the powerful, super-antioxidant star Yumberry (yang-mei in Chinese) also known as red bayberry that's harvested from one hundred-year-old trees and the flavonoid-rich concord grape shown to contain potent antioxidants that may protect against oxidative stress and reduce the risk of free radical damage and chronic diseases."
Regeneca's President, Larry Walter gave his thoughts on the purchase. "From our standpoint, this transaction makes a great deal of sense. The pilot program we completed with Vivakor demonstrated great promise for the product from both a commercial and personal health perspective. Regeneca is certain to be able to develop a strong niche in the nutraceutical market with this terrific product."
About Vivakor, Inc.
Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements, including, but not limited to, statements regarding Vivakor's nutraceutical products and their related market potential. Forward-looking statements may be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Vivakor's filings with the Securities and Exchange Commission, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Vivakor undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.